Athena Bioscience announced plans to launch Nexiclon™ XR, a once-daily, extended-release tablet formulation of clonidine. The Company acquired exclusive rights to commercialize the product from Tris Pharma in February 2021.

Nexiclon XR is a central alpha-adrenergic agonist indicated for the treatment of hypertension as monotherapy or in combination with other antihypertensive agents.

The product is supplied as 0.17mg and 0.26mg tablets, and is expected to be available in April 2022.

“We believe the convenience of a once-daily tablet can contribute to increased patient adherence to medication regimens,” said Jeff Bryant, Athena’s CEO. “Better compliance should provide improved therapeutic outcomes for those suffering from hypertension.”

Reference

Pfizer granted FDA Breakthrough Therapy designation for respiratory syncytial virus (RSV) vaccine candidate for the prevention of RSV in infants from birth up to six months of age by active immunization of pregnant women. News release. Pfizer Inc. Accessed March 2, 2022. https://www.businesswire.com/news/home/20220302005162/en/Pfizer-Granted-FDA-Breakthrough-Therapy-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-Candidate-for-the-Prevention-of-RSV-in-Infants-from-Birth-up-to-Six-Months-of-Age-by-Active-Immunization-of-Pregnant-Women